Show simple item record

dc.contributor.authorKilian, G.
dc.contributor.authorMilne, P.
dc.date.accessioned2016-02-04T09:21:09Z
dc.date.available2016-02-04T09:21:09Z
dc.date.issued2014
dc.identifier.citationKilian, G. & Milne, P. 2014. Optimization of selected liposome-encapsulated diketopiperazines. Journal of drug delivery science and technology, 24(2):143-147. [https://doi.org/10.1016/S1773-2247(14)50023-8]en_US
dc.identifier.issn1773-2447
dc.identifier.urihttp://hdl.handle.net/10394/16141
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1773224714500238
dc.identifier.urihttps://doi.org/10.1016/S1773-2247(14)50023-8
dc.description.abstractResponse surface methodology (RSM) is an effective way to optimize various processes and formulations were investigators are able to determine how variables influence the formulation by assessing interaction effects in order to obtain an optimum formulation. Cyclic dipeptides have been shown to inhibit tumor cells but problems with their physicochemical characteristics have limited further development of these compounds clinically. The aim was to optimize a liposome-based drug delivery system incorporating cyclo(His-Gly) and cyclo(His-Ala) using response surface methodology. Liposomes, containing varying compositions of phosphatidylcholine, cholesterol, stearylamine, vitamin E and PEG2000-phosphatidylethanolamine were prepared according to the thin film hydration and extrusion method. Drugs were passively encapsulated and separated from free drug using Sephadex G50 columns. RSM, utilizing a central composite rotatable design (CCRD) was used to assess the influence of selected variables on encapsulation, uptake, membrane leakage, polydispersity and zeta potential. A quadratic model was used to fit data for all responses. The most significant interaction was between cholesterol and stearylamine content with cellular uptake, indicating that these parameters cannot be altered independently of each other. Optimization of the formulation yielded stable liposomes with an average encapsulation of 0.123 mg drug/mg lipiden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectCentral composite rotatable designen_US
dc.subjectcholesterolen_US
dc.subjectCyclic dipeptidesen_US
dc.subjectCyclo(His; Ala)en_US
dc.subjectPhospholipidsen_US
dc.subjectResponse surface methodologyen_US
dc.subjectStearylamineen_US
dc.titleOptimization of selected liposome-encapsulated diketopiperazinesen_US
dc.typeArticleen_US
dc.contributor.researchID10119620 - Milne, Petrus Jakobus


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record